Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS)

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 3, Issue , 2016, Pages 73-82

  Li, Danni ^a   Misialek, Jeffrey R ^b   Boerwinkle, Eric ^c   Gottesman, Rebecca F ^d   Sharrett, A Richey ^e   Mosley, Thomas H ^f   Coresh, Josef ^e   Wruck, Lisa M ^g   Knopman, David S ^h   Alonso, Alvaro ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h MAYO CLINIC   (United States)

Author keywords

AD; Alzheimer's disease; ARIC; ARIC NCS; Dementia; MCI; Metabolites; Metabolomics; Mild cognitive impairment; Phospholipids; Plasma

Indexed keywords

ANTIHYPERTENSIVE AGENT; PHOSPHOLIPID;

AGED; ARTICLE; CLINICAL DEMENTIA RATING; CLINICAL PROTOCOL; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMENTIA; DISEASE ASSOCIATION; EDUCATION; FEMALE; FUNCTIONAL ASSESSMENT; GENOTYPE; HUMAN; HYPERTENSION; INFORMED CONSENT; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHOLIPID BLOOD LEVEL; PHYSICAL EXAMINATION; PREVALENCE; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

EID: 84975517266     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2016.02.008     Document Type: Article

References (25)

1. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm 2000, 107:1027-1063.
2. Pettegrew J.W., Panchalingam K., Hamilton R.L., McClure R.J. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 2001, 26:771-782.
3. Grimm M.O., Grösgen S., Riemenschneider M., Tanila H., Grimm H.S., Hartmann T. From brain to food: Analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. J Chromatogr A 2011, 1218:7713-7722.
4. Muldoon M.F., Ryan C.M., Sheu L., Yao J.K., Conklin S.M., Manuck S.B. Serum phospholipid docosahexaenonic acid is associated with cognitive functioning during middle adulthood. J Nutr 2010, 140:848-853.
5. Beydoun M.A., Kaufman J.S., Satia J.A., Rosamond W., Folsom A.R. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 2007, 85:1103-1111.
6. Schaefer E.J., Bongard V., Beiser A.S., Lamon-Fava S., Robins S.J., Au R., et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006, 63:1545-1550.
7. Mapstone M., Cheema A.K., Fiandaca M.S., Zhong X., Mhyre T.R., MacArthur L.H., et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 2014, 20:415-418.
8. Klavins K., Koal T., Dallmann G., Marksteiner J., Kemmler G., Humpel C. The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2015, 1:295-302.
9. Olazarán J., Gil-de-Gómez L., Rodríguez-Martín A., Valentí-Soler M., Frades-Payo B., Marín-Muñoz J., et al. A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease. J Alzheimers Dis 2015, 45:1157-1173.
10. Proitsi P., Kim M., Whiley L., Pritchard M., Leung R., Soininen H., et al. Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease. Transl Psychiatry 2015, 5:e494-e502.
11. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989, 129:687-702. Investigators.
12. Schneider A.L., Sharrett A.R., Gottesman R.F., Coresh J., Coker L., Wruck L., et al. Normative data for 8 neuropsychological tests in older blacks and whites from the Atherosclerosis Risk in Communities (ARIC) study. Alzheimer Dis Assoc Disord 2015, 29:32-44.
13. Knopman D.S., Gottesman R.F., Sharrett A.R., Wruck L.M., Windham B.G., Coker L., et al. Mild cognitive impairment and dementia prevalence: The Atherosclerosis Risk in Communities Neurocognitive Study. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2016, 2:1-11.
14. Hainline A., Karon J., Lippel K. Manual of Laboratory Operations: Lipid Research Clinics Program and Lipid and Lipoprotein Analysis 1982, 628. US Department of Health and Human Services, Bethesda, MD.
15. Yin P., Peter A., Franken H., Zhao X., Neukamm S.S., Rosenbaum L., et al. Preanalytical aspects and sample quality assessment in metabolomics studies of human blood. Clin Chem 2013, 59:833-845.
16. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
17. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
18. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
19. Mielke M.M., Bandaru V.V., Haughey N.J., Rabins P.V., Lyketsos C.G., Carlson M.C. Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging 2010, 31:17-24.
20. Mielke M.M., Haughey N.J., Bandaru V.V.R., Weinberg D.D., Darby E., Zaidi N., et al. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis 2011, 27:259.
21. Haskell W.L. The influence of exercise training on plasma lipids and lipoproteins in health and disease. Acta Med Scand Suppl 1986, 220:25-37.
22. Lands W.E., Libelt B., Morris A., Kramer N.C., Prewitt T.E., Bowen P., et al. Maintenance of lower proportions of (n- 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n- 3) fatty acids. Biochim Biophys Acta 1992, 1180:147-162.
23. Grimsgaard S., Bønaa K.H., Jacobsen B.K., Bjerve K.S. Plasma saturated and linoleic fatty acids are independently associated with blood pressure. Hypertension 1999, 34:478-483.
24. Lemaitre R.N., King I.B., Mozaffarian D., Sotoodehnia N., Rea T.D., Kuller L.H., et al. Plasma phospholipid trans fatty acids, fatal ischemic heart disease, and sudden cardiac death in older adults the cardiovascular health study. Circulation 2006, 114:209-215.
25. Brown H.A., Murphy R.C. Working towards an exegesis for lipids in biology. Nat Chem Biol 2009, 5:602-606.